Abstract:Background A therapeutic revolution in the past decade is still a considerable unmet need in the treatment of rheumatoid arthritis (RA). On the other hand, dysfunction of regulatory T cells (Tregs) has been considered to be a pivotal cause of RA and correction of this dysfunction to be a potential RA therapy1. However, abnormalities of Tregs in patients with RA were reported controversially in previous studies2, in which only proportion was measured and Tregs were defined using different protein markers. Objectives In this study, we measured both absolute numbers and proportions of CD4+CD25+Foxp3+ Tregs in peripheral blood of RA patients and investigated the effects of low-dose recombinant human IL-2 (rhIL-2) on Tregs and CD4+ effector T cell subsets in patients with RA. Methods Both absolute numbers and proportions of Treg and Th17 cells in peripheral blood, defined as the CD4+CD25+FOXp3+T or CD4+IL-17 + T cell population, were examined by flow cytometry in 342 patients with RA with different 28-joint Disease Activities (DAS28), including 75 who had never received disease-modifying antirheumatic drugs (DMARD) and 151 who were receiving or had received DMARD. Among these patients, 112 consented at enrollment to receive rhIL-2 treatment. Before and after treatment, the Th17 and Treg cells in peripheral blood were analyzed by flow cytometry. Results The absolute count of Treg cells in patients with RA was significantly low compared with that of healthy controls (P<0.05), but the absolute count of Th17 cell was no different between RA and healthy controls. After the course of rhIL-2 treatment, there was a significant increase in the absolute count of Th17 and Treg cells in the CD4+ T cell population (P<0.01), but Th17/Treg was significantly low after the treatment. Conclusions The data suggest that, besides propotion, the decrease of Treg cell number, defined as the CD4+CD25+FOXp3+population, may contribute to the pathogenesis of RA. Over the treatment of rhIL-2, there was a more significant increase in the absolute count of Treg cells than that of Th17, and consequently restore the balance of Th17/Treg. References Miyara M, Ito Y, Sakaguchi S. TREG-cell therapies for autoimmune rheumatic diseases. Nature reviews Rheumatology 2014;10:543–51. Morita T, Shima Y, Wing JB, Sakaguchi S, Ogata A, Kumanogoh A. The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis. PloS one 2016;11:e0162306. Disclosure of Interest None declared

TREG-cell therapies for autoimmune rheumatic diseases

Tgf-Beta-Induced Regulatory T Cells Directly Suppress B Cell Responses Through A Noncytotoxic Mechanism

Treg Enhancing Therapies to Treat Autoimmune Diseases

The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases

SAT0213 Low Dose Il-2 Restores Decreased Absolute Number of Regulatory T Cells and Imbalance Between Th17 and Regulatory T Cells in Patients with Rheumatoid Arthritis

Treg cell therapy: How cell heterogeneity can make the difference

Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders – Advances and challenges

Current status and perspectives of regulatory T cell-based therapy

Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases

T regulatory cells as an immunotherapy for transplantation.

Regulatory T lymphocytes as a treatment method for rheumatoid arthritis - Superiority of allogeneic to autologous cells

Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential

Therapy with regulatory T-cell infusion in autoimmune diseases and organ transplantation: A review of the strengths and limitations

Induced Regulatory T Cells as Immunotherapy in Allotransplantation and Autoimmunity: Challenges and Opportunities

T Regulatory Cells As an Immunotherapy for Transplantation

Interleukin-2 and regulatory T cells in rheumatic diseases

A Novel Subset of Regulatory T Cells Induced by B Cells Alleviate the Severity of Immunological Diseases

Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases

Research Progress on Regulatory T Cells and Their Relationship with Autoimmune Diseases

The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases

Regulatory T cells: Development, function and role in autoimmunity